Fexoril

Quick links to important sections

Fexoril

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fexoril

What is Fexoril? Defining its Identity and Purpose

Property Description
Active Ingredient Fexofenadine Hydrochloride
Form Oral (Tablet, Capsule, Suspension)
Pharmacological Class Second-Generation Antihistamine (H1-receptor antagonist)
Common Use Relief of symptoms associated with allergic reactions
Origin Synthetic (Metabolite of Terfenadine)

What is Fexoril and its Chemical Identity?

Fexoril is a pharmaceutical preparation whose primary role is to act as an effective antihistamine in the body, counteracting the chemicals responsible for allergic reactions. Its core active compound is Fexofenadine Hydrochloride, a synthetic, single-ingredient product derived from the active metabolite of the older antihistamine, terfenadine. Fexoril is classified as a second-generation H1-receptor antagonist, a modern pharmacological class engineered for high specificity. This classification ensures that the medication directly targets peripheral H1 receptors, providing a specialized action to manage the allergic response.

The Purpose and Forms of Fexoril

The main general purpose of Fexoril is to provide relief from the core symptoms associated with various allergic conditions by performing selective histamine blockade throughout the body. The mechanism successfully prevents histamine, released during an allergic response, from binding to its receptors and triggering symptoms, which is clinically recognized for its role in allergy management. This action provides effective relief from manifestations like itching and sneezing. For the purpose of ingestion, Fexoril is designed for oral administration and is supplied in several pharmaceutical preparations, including the solid tablet and capsule forms, as well as an oral suspension often geared towards pediatric and geriatric user groups who may require a liquid vehicle.

Why Fexoril is Classified as Non-Sedating

Fexoril is categorized as a nonsedating antihistamine due to a specific design feature related to its physiological action. The Fexofenadine molecule is chemically structured to exhibit minimal crossing of the blood-brain barrier. This characteristic is crucial because it significantly restricts the drug's access to the central nervous system, thus reducing the potential for inducing the drowsiness or cognitive impairment that is often associated with older, first-generation antihistamine compounds. This chemical differentiation supports its use when maintaining alertness is necessary.

Regulatory References

  1. Fexofenadine: MedlinePlus Drug Information

What side effects are possible with Fexoril?

Possible Side Effects and Safety Information

The safety profile of Fexoril (Fexofenadine Hydrochloride) is established through frequency classification and grouping by the affected system organ class (SOC) in official regulatory documents. This approach differentiates common events observed in clinical trials from rare, serious reactions reported during post-marketing surveillance.


Frequency and System Classification

Adverse reactions are primarily classified by frequency and grouped into System-Organ Classes:

Classification Common Adverse Reactions (Adults/Adolescents) Affected System-Organ Classes
Common Headache, Dizziness, Back Pain, Stomach Discomfort, Pain in Extremity Nervous System (e.g., Headache), Gastrointestinal (e.g., Stomach Discomfort), Musculoskeletal (e.g., Back Pain)
Rare Systemic Hypersensitivity Reactions Immune System/Skin (e.g., Rashes, Angioedema), Cardiac (e.g., Arrhythmias)

Serious Adverse Reactions and Safety Constraints

The official labeling documents rare but clinically significant events, including Systemic Hypersensitivity Reactions such as Angioedema and Anaphylaxis, and reports of Ventricular Arrhythmias, particularly when used in the context of specific drug interactions.

Regulatory restrictions note that Fexoril is generally contraindicated in patients with known hypersensitivity to its components, or with pre-existing cardiac disease or conditions that cause QT interval prolongation or electrolyte imbalances.

Population-Specific Safety Notes

The prescribing information includes specific warnings for certain populations. Patients with Renal Impairment require particular consideration because of a documented prolonged elimination half-life and increased plasma concentrations, necessitating dosage adjustment. Caution is advised for Older Adults due to the increased likelihood of age-related decreased renal function. The safety profile for Pediatric Patients (6 months to 11 years) includes distinct common events such as Cough, Otitis Media, and Pyrexia (fever).

Overdose and Emergency Response

Fexoril Overdose and When to Seek Help

This information is based on official government regulatory documents detailing the management of fexofenadine overdose.


Documented Overdose Presentations

Regulatory reports of fexofenadine overdose have been infrequent and contain limited clinical information. The manifestations most often reported in cases of overdose include dizziness, drowsiness (somnolence), and dry mouth. While single doses of up to 800 mg have been administered to human subjects without resulting in clinically significant adverse events, any suspected overdose should be treated as an emergency.


Required Emergency Action

Immediate medical help must be sought or a Poison Control Center must be contacted right away in the event of any suspected overdose. Emergency management is based on established protocols aimed at reducing drug absorption and providing supportive care.

Management Action Official Regulatory Statement
Drug Removal Standard measures to remove any unabsorbed drug should be considered.
Support Symptomatic and supportive treatment is recommended.
Ineffective Method Hemodialysis is not an effective method for removing fexofenadine and is of no benefit.

This framework ensures that any potential overdose is assessed immediately by healthcare professionals, even when the reported symptoms are mild or non-specific.

Therapeutic Uses of Fexoril

What Fexoril Treats: Main Uses and Benefits

Fexoril is commonly used for symptomatic relief in key allergic domains. The medication is generally applied in situations involving certain distressing symptoms across conditions, including Seasonal Allergic Rhinitis (hay fever) and Chronic Idiopathic Urticaria (hives).

It helps address symptom clusters that may become intense or disruptive, such as repetitive sneezing, profuse runny nose, persistent itching of the nose, throat, or skin, and the associated symptoms of itchy and watery eyes. It is used in areas where short-term symptom management is appropriate, and may assist patients with managing difficult episodes and symptoms that interfere with daily functioning.

“This approach is relevant in contexts where additional symptomatic support is needed, particularly when allergic symptoms create noticeable functional strain.”

Fexoril is relevant in settings where supportive symptom management is needed and where symptoms that interfere with daily functioning are present, as it is associated with a reduced potential for sedation. It provides support that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Relief for Disruptive Allergic Symptoms

The primary therapeutic benefit is to support the management of key allergic manifestations, contributing to improved comfort during symptomatic periods, and supporting the maintenance of functional stability.

Eligibility and Restrictions for Use

Who Can and Cannot Use Fexoril?

Eligibility for Fexoril (Fexofenadine Hydrochloride) is strictly defined by regulatory criteria, encompassing age, physiological status, and pre-existing conditions.

Contraindications and Restrictions

Classification Population/Condition Regulatory Status
Absolute Contraindication Known hypersensitivity to Fexofenadine or any excipient Prohibited
Pediatric Restriction Infants under 6 months of age Not Recommended/Not Established

Age-Specific and Conditional Eligibility

Fexoril is approved for use in Adults and Adolescents (12 years and older) for both Seasonal Allergic Rhinitis (SAR) and Chronic Idiopathic Urticaria (CIU). For children, eligibility varies by indication: approved for CIU starting at 6 months, but for SAR starting at 2 years of age.

Use is not recommended in pregnancy or by nursing mothers unless strictly necessary, due to limited human data. Patients with decreased renal function (kidney impairment) or hepatic impairment should use the medicine with caution, as the regulatory label advises administering the drug with care in these populations. Additionally, patients with a history of cardiovascular disease should exercise caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fexoril's officially documented interaction profile is primarily defined by pharmacokinetic interactions that alter the concentration of the drug in the body. The medication undergoes minimal metabolism, and therefore, regulatory labels do not document clinically relevant interactions based on Cytochrome P450 (CYP) enzymes or additive pharmacodynamic effects.

Documented Exposure-Modifying Substances

Interacting Substance Official Interaction Outcome Mechanism Classification
Erythromycin and Ketoconazole Increased systemic plasma exposure (Cmax and AUC) Transporter-Mediated (P-glycoprotein inhibition)
Aluminum/Magnesium Antacids Reduced systemic plasma exposure Reduced Gastrointestinal Absorption
Fruit Juices (Apple, Orange, Grapefruit) Reduced systemic plasma exposure Transporter-Mediated (OATP uptake inhibition)

The co-administration of Erythromycin or Ketoconazole is documented to increase Fexoril's concentration through inhibitory effects on P-glycoprotein (P-gp) and enhanced absorption. Conversely, simultaneous use of aluminum- and magnesium-containing antacids significantly reduces Fexoril's absorption. This reduction requires a mandatory administration rule: Fexoril must be separated from these antacids by at least 2 hours. Furthermore, fruit juices reduce bioavailability due to interference with intestinal uptake transporters. Official labeling notes that because Fexoril is primarily eliminated by the kidneys, patients with impaired renal function may face a greater risk of increased exposure.

Mechanism of Action

How Fexoril Works

Selective H1 Receptor Blockade

Fexoril exerts its primary mechanism by acting as a selective competitive antagonist at the peripheral Histamine H1-receptor. This molecular action functionally blocks the receptor, preventing endogenous histamine from initiating H1-mediated signal transduction.

Influencing Histamine-Driven Vascular Dynamics

The antagonism of peripheral H1 receptors on endothelial cells modulates inflammatory pathways, which influences the dynamics of vascular permeability and vasodilation. The mechanism restricts H1-mediated plasma extravasation and reduces the H1-mediated excitation of peripheral sensory nerves.

Peripheral-Focused Mechanism

The molecule is designed with high polarity and is subject to active efflux by P-glycoprotein, effectively restricting its passage across the blood-brain barrier (BBB). This mechanism ensures the drug's action is concentrated on peripheral tissues, minimizing interaction with central H1 receptors, a factor that determines its classification as having low Central Nervous System (CNS) activity.

Dosage and Administration Information

How to Use Fexoril

The administration of Fexoril (Fexofenadine Hydrochloride) is governed by specific instructions defining standardized use patterns.

Fexoril is exclusively intended for oral administration and is available in forms such as tablets, capsules, and an oral suspension.


Official Dosing and Frequency

Population Standard Dosing Regimen Frequency
Adults and Adolescents (ge 12 years) 180 mg or 60 mg Once daily or Twice daily
Pediatric (Ages 6 to 11 years) 30 mg Twice daily

For adults and adolescents, the dosage is either 180 mg taken once daily or 60 mg taken twice daily. A lower dose of 60 mg once daily is often specified as the starting regimen for patients with reduced kidney function. Pediatric patients typically use a 30 mg dose administered twice daily.


Contextual Administration Rules

The medicine is generally taken with water and may be taken without regard to meals. However, it is noted that Fexoril should not be taken with fruit juices (including grapefruit, apple, or orange juice), as these may reduce the absorption of the active ingredient. Furthermore, to maintain proper absorption, the dose must be separated by at least two hours from the intake of antacids that contain aluminum or magnesium.

If using the oral suspension, the container should be shaken well before measuring. If a dose is missed, individuals should resume the scheduled dosing time and not take a double dose to compensate. These procedural rules ensure the correct and reliable use of the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fexoril


Evidence for Use in Seasonal Allergic Rhinitis (SAR)

Research has primarily focused on examining Fexoril for symptoms associated with Seasonal Allergic Rhinitis. The evidence relies on a large number of short-term, randomized controlled trials (RCTs) comparing Fexoril against a placebo. Researchers monitored outcomes related to physical discomfort, primarily through symptom scoring systems for sneezing, runny nose, and itching, and examined patient-reported experiences related to daily functioning. Findings describe patterns observed in the studies where individuals who received Fexoril reported differences in symptom scores. The consistency of findings across these studies means the evidence level is described as High in regulatory summaries. However, evidence quality varies across studies, and some aspects remain uncertain.


Evidence for Use in Chronic Idiopathic Urticaria (CIU)

Fexoril was also evaluated in studies for its use in Chronic Idiopathic Urticaria (CIU), a condition marked by cycles of stability and flare-ups (hives). Research involved randomized, placebo-controlled trials typically observing responses over four to six weeks. The primary outcomes related to physical discomfort that research examined included the severity of itching (pruritus) and the number and size of wheals (hives). The studies were consistently described in regulatory reviews as having sufficient evidence to support a coarse evidence designation of High. While symptomatic patterns are described, the data for certain groups remain insufficient, and comparative evidence is lacking.


Long-Term Studies and Follow-up Duration

The majority of the core evidence for both indications is rooted in short-term clinical trials, typically lasting two to six weeks. These short follow-up durations were limited to assessing acute symptomatic change. Evidence beyond these periods comes mainly from observational settings, which contributes to understanding symptom patterns over time but does not provide the same level of structured data. Therefore, long-term effects are not fully established.


Evidence in Specific Patient Populations

The key efficacy trials included populations of adults and adolescents in large numbers. Separate studies were also evaluated in populations of children (6-to-11-year age range). However, the data for certain groups remain insufficient, particularly for very young children (under 6 years), where evidence is more limited or less direct compared to the adult and adolescent populations.


Research Gaps and Areas of Uncertainty

A review of the research indicates several areas where knowledge is still emerging. Subgroup findings are uncertain for specific patient groups, and establishing a clear link between dose escalation and symptomatic change in non-responders appears to require further study. The scientific community continues to explore the relative performance of different antihistamines, and a universally conclusive ranking is not fully established.

Frequently Asked Questions (FAQ)

Common questions about Fexoril (FAQ)


Q: Is Fexoril a maintenance drug or an as-needed treatment?

A: Official information indicates Fexoril is approved to treat two main conditions: Seasonal Allergic Rhinitis (SAR) and Chronic Idiopathic Urticaria (CIU). SAR symptoms often require intermittent use, while the management of chronic conditions like CIU may require consistent daily administration. The necessary duration of use depends on the condition being addressed.


Q: Is Fexoril considered a controlled substance?

A: According to regulatory documents from bodies like the U.S. Drug Enforcement Administration (DEA), Fexoril is not classified as a controlled substance. This means its distribution and prescribing are not regulated under the Controlled Substances Act.


Q: What does it mean if Fexoril has a Black Box Warning?

A: Fexoril does not have a Black Box Warning from the Food and Drug Administration (FDA). This warning is a requirement for serious or life-threatening risks. Fexoril was developed as a metabolite of the first-generation antihistamine terfenadine; this design change was intended to minimize the specific cardiac risks associated with terfenadine.


Q: Can I take over-the-counter pain relievers or cold medicine with Fexoril?

A: The official drug label does not list documented interactions with every type of non-prescription pain reliever. Regulatory caution generally suggests avoiding combination cold or allergy products that already contain another antihistamine. Using multiple antihistamines at once may increase the overall risk of side effects from that drug class.


Q: Does Fexoril interact with vitamins or herbal supplements like St. John's Wort?

A: Specific warnings for individual vitamins or herbal supplements are not generally included on the Fexoril regulatory label. Official labeling notes that caution is included for use with products, including herbal remedies, that may cause additive effects such as drowsiness or dry mouth.


Q: How long does it typically take for Fexoril to start working?

A: Studies included in the regulatory documentation show that an antihistamine effect can begin to be observed within one hour of administration. The point of highest concentration, known as Cmax, is generally observed approximately two to three hours after the dose is taken.


Q: Why do some users on forums say Fexoril makes them feel worse initially?

A: Like any medication, Fexoril may be associated with common adverse reactions, particularly when first starting treatment. Official safety information lists common side effects, including headache, dizziness, and stomach discomfort. These common reactions are generally described as mild in clinical trial data.


Q: Can Fexoril be crushed or split if a person has trouble swallowing pills?

A: Regulatory instructions state that the solid forms of Fexoril, such as tablets and capsules, are meant to be swallowed whole. Unless a different instruction is given by a medical professional, tablets should generally not be crushed, split, or chewed. If swallowing is difficult, the oral suspension form may be an alternative option.


Q: Does Fexoril work for all stages of [the condition it treats]?

A: Official labeling indicates that Fexoril is approved for its ability to provide symptomatic relief from allergic conditions by blocking histamine. Regulatory information describes its use as symptomatic relief, and the evidence does not address altering the long-term progression or 'stages' of the underlying condition.


Q: Why do people report different experiences with Fexoril?

A: Individual responses to Fexoril may vary due to several factors cited in regulatory and clinical reviews. These can include normal variations in a person's metabolism and the use of other products, such as certain fruit juices or antacids, which are known to affect drug concentration. Official research reports mention that differences in symptomatic response can be observed among various patient subgroups.


Q: Is it common to have an initial adjustment period when starting Fexoril?

A: An initial adjustment period is possible when starting any medication. Official safety profiles for Fexoril list common adverse events that occur in clinical trials, such as headache and dizziness. These effects are generally described as mild and may be more noticeable at the start of treatment.


Q: Does Fexoril have an effect on fertility?

A: Official non-clinical data included in regulatory submissions have specifically evaluated the potential for Fexoril to affect reproductive health. Studies performed in animal models did not show impairment to either female or male fertility. Specific human studies focusing on the effects of Fexoril on fertility have not been conducted.


Q: How do I know if Fexoril is the right drug class for my condition?

A: Fexoril belongs to the pharmacological class of Second-Generation Antihistamines (H1-receptor antagonists). This class of medication is specifically designed to treat symptoms caused by the body's release of histamine during allergic reactions. Therefore, it is officially indicated for conditions where symptom relief is achieved by blocking the action of histamine.

How should Fexoril be stored and disposed of?

Storage and Disposal Requirements for Fexoril

Official regulatory labeling dictates specific conditions for storing Fexoril (Fexofenadine Hydrochloride) to ensure stability and safety.

Requirement Official Statement Summary
Storage Temperature Store at controlled room temperature (20–25°C or 68–77°F).
Protection & Container Keep the product in its original container, which must be well-closed and light-resistant.
Child Safety Keep out of the sight and reach of children at all times.
Shelf-Life A typical shelf-life of three years is supported when stored under the specified conditions.

Disposal must also follow regulatory guidelines. Unused or expired Fexoril must not be thrown away via wastewater or household waste. It is officially required to ask a pharmacist for disposal methods that align with local/regional/national regulations to protect the environment. These guidelines ensure the product maintains its labeled stability and is safely removed from the home.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fexoril found in:

A-Z Index: